Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.

Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK.

Lancet. 1999 Sep 18;354(9183):975-8.

PMID:
10501358
3.

Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.

Li J, Coates RJ, Gwinn M, Khoury MJ.

Am J Epidemiol. 2010 Jan 1;171(1):1-13. doi: 10.1093/aje/kwp318. Epub 2009 Nov 13. Review.

PMID:
19914946
4.

Pharmacogenetics of human androgens and prostatic diseases.

Novelli G, Margiotti K, Sangiuolo F, Reichardt JK.

Pharmacogenomics. 2001 Feb;2(1):65-72. Review.

PMID:
11258198
5.

Genetic polymorphisms and prostate cancer risk.

Gsur A, Feik E, Madersbacher S.

World J Urol. 2004 Feb;21(6):414-23. Epub 2003 Nov 26. Review.

PMID:
14648103
6.

SRD5A2 gene mutations--a population-based review.

Samtani R, Bajpai M, Ghosh PK, Saraswathy KN.

Pediatr Endocrinol Rev. 2010 Sep;8(1):34-40. Review.

PMID:
21037542
7.

The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.

Platz EA, Giovannucci E.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):237-53. Epub 2005 Jan 5. Review.

PMID:
15663987
8.

CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.

Keshava C, McCanlies EC, Weston A.

Am J Epidemiol. 2004 Nov 1;160(9):825-41. Review.

PMID:
15496535
9.

Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Pettaway CA.

J Natl Med Assoc. 1999 Dec;91(12):653-60. Review.

10.

Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes.

Ntais C, Polycarpou A, Tsatsoulis A.

Eur J Endocrinol. 2003 Dec;149(6):469-77. Review.

11.

Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression.

Makridakis NM, Reichardt JK.

J Urol. 2004 Feb;171(2 Pt 2):S25-8; discussion S28-9. Review.

PMID:
14713749
12.

Prostate cancer in men of African origin.

McGinley KF, Tay KJ, Moul JW.

Nat Rev Urol. 2016 Feb;13(2):99-107. doi: 10.1038/nrurol.2015.298. Epub 2015 Dec 31. Review.

PMID:
26718455
13.

Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.

Hulin-Curtis SL, Petit D, Figg WD, Hsing AW, Reichardt JK.

Future Oncol. 2010 Dec;6(12):1897-913. doi: 10.2217/fon.10.149. Review.

PMID:
21142863
14.

Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling.

Nwaneri AC, McBeth L, Hinds TD Jr.

Horm Cancer. 2016 Dec;7(5-6):296-304. Epub 2016 Jul 22. Review.

PMID:
27447901
15.

Genotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate Cancer.

López-Cortés A, Cabrera-Andrade A, Salazar-Ruales C, Zambrano AK, Guerrero S, Guevara P, Leone PE, Paz-Y-Miño C.

Biomed Res Int. 2017;2017:3507671. doi: 10.1155/2017/3507671. Epub 2017 Jun 8. Review.

16.

Pharmacogenetics of human androgens and prostate cancer--an update.

Novelli G, Margiotti K, Chiocca AM, Spera E, Micali F, Reichardt JK.

Pharmacogenomics. 2004 Apr;5(3):283-94. Review.

PMID:
15102543
17.

[Prospects of genetic polymorphism analyses in prostatic disease].

Kagawa S, Nishitani MA.

Nihon Rinsho. 2002 Dec;60 Suppl 11:474-8. Review. Japanese. No abstract available.

PMID:
12599622

Supplemental Content

Support Center